Skip to main content
. Author manuscript; available in PMC: 2014 Jun 15.
Published in final edited form as: J Immunol. 2013 May 17;190(12):6681–6693. doi: 10.4049/jimmunol.1201363

Figure 4. CCL17 and CCL22 are increased in the serum of FL patients and CCL22 is predictive of inferior progression-free survival.

Figure 4

The levels of CCL17 (A) and CCL22 (B) were determined by ELISA in the serum of FL patients at diagnosis (n = 38) and in normal donors (ND, n = 11). The horizontal bars represent the mean values for each group. Statistical significance was determined by Wilcoxon rank-sum test. (C and D) Kaplan-Meier survival curves for progression free survival (PFS) in FL patients with high (> median, n = 19) and low (≤ median, n = 19) serum levels of CCL17 and CCL22 at diagnosis and treated uniformly with prednisone, doxorubicin, cyclophosphamide, and etoposide chemotherapy followed by autologous tumor-derived idiotype vaccination are shown. P value was calculated by log-rank test.